This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Checkpoint immunotherapy — blocking inhibitory receptors like PD-1, PD-L1, and CTLA-4 to unleash anti-tumor T cells — has transformed oncology since the first anti-CTLA-4 approval in 2011. Yet most patients across most tumor types still do not derive durable benefit from single-agent checkpoint inhibition. In 2026, the clinical trial landscape is dominated by combination strategies: dual checkpoint blockade, novel co-inhibitory targets (LAG-3, TIM-3, TIGIT), bispecific antibodies that simultaneously engage two immune pathways, therapeutic cancer vaccines, and cell therapy combinations that aim to overcome the tumor microenvironment's suppressive machinery.
Why Single-Agent Checkpoint Blockade Falls Short
PD-1/PD-L1 inhibitors achieve durable responses in a minority of patients across most tumor types — typically 20–40% in PD-L1-high tumors, substantially less in unselected populations. Primary resistance mechanisms include: absence of pre-existing tumor-infiltrating lymphocytes (TIL, "cold" tumors); loss of antigen presentation (beta-2 microglobulin loss, HLA downregulation); alternative co-inhibitory checkpoint upregulation (LAG-3, TIM-3, TIGIT, VISTA); immunosuppressive cellular populations in the tumor microenvironment (regulatory T cells, M2-polarized macrophages, myeloid-derived suppressor cells); and WNT/beta-catenin signaling that excludes T cells from tumors.
The rational next step is combination immunotherapy: adding a second checkpoint inhibitor, a co-stimulatory agonist, a tumor-targeted agent that increases immunogenicity, or a stromal modifier that improves T cell infiltration. The challenge is that combination immune therapies frequently amplify immune-related adverse events (irAEs) — colitis, hepatitis, pneumonitis, endocrinopathies — requiring careful dose optimization and patient selection. The field has learned that additive or synergistic anti-tumor activity does not necessarily require additive toxicity if mechanisms are chosen wisely.
Dual Checkpoint Blockade: Nivolumab Plus Ipilimumab and Evolving Regimens
The combination of nivolumab (PD-1 inhibitor, Bristol Myers Squibb) plus ipilimumab (CTLA-4 inhibitor) established the proof of concept for dual checkpoint blockade in melanoma, where it achieves a 5-year overall survival rate of ~52% — double what was seen with chemotherapy in the pre-immunotherapy era. CHECKMATE-227 extended this combination to non-small cell lung cancer (NSCLC), demonstrating significantly improved OS versus platinum-based chemotherapy in PD-L1-high tumors (OS HR 0.79). CHECKMATE-9LA added two cycles of chemotherapy to nivolumab/ipilimumab to bridge the gap before immunotherapy takes effect, improving early landmark survival rates.
In 2026, the key question is whether lower doses of ipilimumab (1 mg/kg instead of 3 mg/kg) can maintain efficacy while significantly reducing grade 3–4 irAEs. The TITAN-1 trial is directly comparing 1 mg/kg versus 3 mg/kg ipilimumab combined with nivolumab in NSCLC, powered to show non-inferiority on OS with superiority on treatment-related adverse events. Additionally, relatlimab (LAG-3 inhibitor) plus nivolumab (Opdualag) — approved in 2022 for melanoma — is being evaluated vs. nivolumab/ipilimumab in the RELATIVITY-048 trial, with the hypothesis that LAG-3 blockade provides similar synergy to CTLA-4 blockade with a more favorable toxicity profile.
Novel Checkpoint Targets: TIGIT, TIM-3, and VISTA
After LAG-3, TIGIT (T cell immunoreceptor with Ig and ITIM domains) and TIM-3 (T cell immunoglobulin and mucin domain-3) are the most advanced novel checkpoint targets in clinical development. TIGIT is expressed on exhausted T cells and NK cells, and its ligand PVR is upregulated on tumor cells and APCs in the tumor microenvironment. Tiragolumab (Genentech) combined with atezolizumab showed early promise in NSCLC (CITYSCAPE Phase 2), but the Phase 3 SKYSCRAPER-01 trial failed to meet its primary endpoint of improved PFS or OS in PD-L1-high NSCLC — a significant setback.
Despite SKYSCRAPER-01's failure, TIGIT remains an active target. Domvanalimab (ARC-7, Arcus Biosciences) — an Fc-silent anti-TIGIT designed to avoid NK cell depletion via ADCC — in combination with zimberelimab (PD-1 inhibitor) is in the STAR-221 Phase 3 trial for first-line NSCLC, reporting data in 2026. Vibostolimab (anti-TIGIT, Merck) plus pembrolizumab is in Phase 3 for NSCLC and cervical cancer. For TIM-3, cobolimab (GSK) plus dostarlimab Phase 2 trials have shown early activity signals in AML and NSCLC, with Phase 3 enrollment underway. The VISTA target (V-domain Ig suppressor of T cell activation) is being addressed by CA-170 (small molecule) and several monoclonal antibodies in early Phase trials.
Bispecific Antibodies: Engaging Two Pathways Simultaneously
Bispecific antibodies can be engineered to simultaneously block two co-inhibitory checkpoints, or to redirect T cells to tumors while co-stimulating them. Cadonilimab (AK104, Akeso) simultaneously blocks PD-1 and CTLA-4 with a single molecule designed to preferentially accumulate in the tumor microenvironment where both ligands are co-expressed, potentially offering dual checkpoint blockade with reduced systemic CTLA-4 toxicity. Phase 2 data in cervical cancer showed a 33% ORR in PD-L1-positive recurrent/metastatic disease; Phase 3 enrollment in cervical cancer and gastric cancer is ongoing.
The T cell engager class (TCEs or bispecific T cell engagers, BiTEs) — exemplified by blinatumomab (CD19xCD3) in ALL — is being extended to solid tumor indications using PD-1 or 4-1BB co-stimulation arms. Tarlatamab (DLL3xCD3, Amgen) redirects T cells to DLL3-expressing small cell lung cancer cells. The DeLLphi-301 Phase 2 trial demonstrated a 40% ORR in patients with two or more prior therapies, with FDA granting accelerated approval in May 2024. Phase 3 trials (DeLLphi-304) are now comparing tarlatamab to topotecan/irinotecan as second-line SCLC therapy. HER2-targeted TCEs and EGFR-targeted bispecifics are in Phase 1/2 for breast, gastric, and lung cancers, exploring whether directing T cells to tumors while relieving checkpoint suppression can overcome cold tumor resistance.
Therapeutic Cancer Vaccines and Checkpoint Combination
The convergence of mRNA vaccine technology (developed for COVID-19) with cancer immunotherapy is one of the most actively pursued areas of 2026 oncology trials. Personalized mRNA neoantigen vaccines — created from each patient's tumor mutational profile — are designed to prime T cells against tumor-specific antigens, then combined with checkpoint inhibitors to sustain the immune response. The mRNA-4157/V940 (Moderna/Merck) personalized neoantigen vaccine combined with pembrolizumab showed a 44% reduction in the risk of recurrence or death compared to pembrolizumab alone in the KEYNOTE-942 Phase 2b trial for resected high-risk melanoma — one of the most striking immunotherapy results of 2024. Phase 3 KEYNOTE-942-003 is now enrolling, and the mRNA-4157 platform is being evaluated in adjuvant lung cancer (NSCLC), bladder cancer, and head and neck cancer in parallel Phase 2 trials.
Fixed neoantigen vaccine platforms are also advancing. The GRANITE trial evaluated a personalized adenoviral/self-amplifying mRNA vaccine (Neon Therapeutics) combined with nivolumab in colorectal cancer; while this program was discontinued, it generated immunological insights guiding next-generation designs. BNT111 (BioNTech), an mRNA vaccine targeting four shared melanoma antigens (NY-ESO-1, MAGE-A3, tyrosinase, TPTE), is in Phase 2 combined with cemiplimab for unresectable stage III/IV melanoma that failed prior PD-1 therapy.
CAR-T Combinations and the Solid Tumor Challenge
CAR-T cell therapy has achieved spectacular results in hematologic malignancies — tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel, and others achieve 50–80% complete remission rates in relapsed/refractory B cell lymphomas and ALL. Extending this to solid tumors has proven far more difficult: the immunosuppressive tumor microenvironment inhibits CAR-T persistence and function, heterogeneous antigen expression allows antigen-loss escape, and solid tumors are harder to penetrate physically.
In 2026, combination strategies aim to address CAR-T dysfunction in solid tumors. The MESO-CAR trial is evaluating mesothelin-directed CAR-T (CART-meso) combined with pembrolizumab in mesothelioma and lung cancer — the checkpoint inhibitor prevents exhaustion of CAR-T cells arriving in an immunosuppressive environment. Armored CAR-T cells that constitutively secrete IL-12, IL-18, or IL-21 to reshape the tumor microenvironment are in Phase 1/2 trials for pancreatic and ovarian cancer. GD2-directed CAR-T combined with anti-GD2 antibody dinutuximab is in Phase 2 for neuroblastoma. The CAR-T plus oncolytic virus strategy — using engineered viruses to lyse tumor cells and create an inflammatory microenvironment that supports CAR-T function — is in Phase 1 for glioblastoma and colorectal cancer.
Key Takeaways
- Dual checkpoint blockade (nivolumab/ipilimumab) remains the standard in melanoma and is standard or guideline-included in NSCLC and other solid tumors; optimization trials are exploring lower ipilimumab doses and LAG-3 as an alternative partner.
- Despite high expectations, the Phase 3 SKYSCRAPER-01 failure for TIGIT in NSCLC illustrates that positive Phase 2 signals do not always translate; next-generation anti-TIGIT antibodies with modified Fc regions are now in Phase 3 addressing potential confounders.
- Personalized mRNA neoantigen vaccines (mRNA-4157/V940) combined with pembrolizumab reduced melanoma recurrence by 44% in Phase 2b, with Phase 3 enrolling in 2026 across multiple tumor types.
- DLL3xCD3 bispecific tarlatamab achieved accelerated FDA approval in small cell lung cancer (2024) and is in Phase 3 versus standard second-line chemotherapy.
- CAR-T cell combinations with checkpoint inhibitors, cytokine-secreting "armored" constructs, and oncolytic viruses are the leading strategies to overcome solid tumor resistance that has blunted CAR-T efficacy outside hematology.